Cargando…
Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals?
In 2018, an international Task Force formulated recommendations for treating Juvenile Idiopathic Arthritis (JIA) to target. The Task Force has not yet resolved three issues. The first issue is the lack of a single “best” target. The Task Force decided not to recommend the use of a specific instrumen...
Autores principales: | Schoemaker, Casper G., Swart, Joost F., Wulffraat, Nico M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164231/ https://www.ncbi.nlm.nih.gov/pubmed/32299430 http://dx.doi.org/10.1186/s12969-020-00428-7 |
Ejemplares similares
-
What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
por: Swart, Joost F, et al.
Publicado: (2013) -
Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis
por: Swart, Joost F, et al.
Publicado: (2018) -
Patient’s experiences with the care for juvenile idiopathic arthritis across Europe
por: van Dijkhuizen, E. H. Pieter., et al.
Publicado: (2018) -
PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013) -
Monitoring patients with juvenile idiopathic arthritis using health-related quality of life
por: Doeleman, Martijn J. H., et al.
Publicado: (2021)